Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a biosimilar - CinnaGen

Drug Profile

Interferon beta-1a biosimilar - CinnaGen

Alternative Names: CinnoVex; Rec Hu - IFN beta1a

Latest Information Update: 14 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CinnaGen
  • Class Antineoplastics; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 12 Feb 2019 Cinnagen completes phase I trial in Multiple Sclerosis (In volunteers) in Finland (NCT03614715)
  • 22 Feb 2018 CinnaGen initiates a phase III trial for Multiple sclerosis in Iran (IM) (IRCT201612306135N8)
  • 25 Jan 2017 CinnaGen plans a phase III trial for Multiple sclerosis in Iran (IM) (IRCT201612306135N8)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top